title: [A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
abstract: We are performing a phase I clinical trial of combination-therapy with gemcitabine and epitope peptide derived from human vascular endothelial growth factor receptor (VEGFR) for advanced pancreas cancer. The aim of this study was to evaluate the safety, immunological response and tumor response. Six patients have been enrolled at present. During the clinical course, no major adverse events were observed. Additionally, two out of 6 cases showed a minor shrinkage of the tumor. Immunological response has not been analyzed yet. These results indicated that a combination-therapy with gemcitabine and epitope peptides derived from VEGFR could be tolerable.
authors.affiliation: Dept. of Surgery, Tokyo Women's Medical University Medical Center East.
authors.forename: Dal Ho
authors.initials: DH
authors.lastname: Kim
authors.forename: Shunichi
authors.initials: S
authors.lastname: Shiozawa
authors.forename: Takebumi
authors.initials: T
authors.lastname: Usui
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Taisuke
authors.initials: T
authors.lastname: Otani
authors.forename: Takuya
authors.initials: T
authors.lastname: Tsunoda
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D003131:Combined Modality Therapy / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000473:pathology / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D010455:Peptides / Q000009:adverse effects / Q000276:immunology*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000276:immunology*; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D000939:Epitopes; D010455:Peptides; D003841:Deoxycytidine; D040262:Receptors, Vascular Endothelial Growth Factor; D000093542:Gemcitabine